Measuring Atomoxetine and Aroxybutynin In Patients With OSA
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of Atomoxetine/Aroxybutynin (AD109) to Atomoxetine Alone or Placebo in Obstructive Sleep Apnea
| Sponsorer |
Hovedsponsor: Apnimed |
|---|---|
| Kilde | Apnimed |
| Kort oppsummering | MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study of AD109 in participants with OSA. Enrolled participants will be randomized to one of 5 parallel treatment arms. |
| Detaljert beskrivelse | MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study in participants with OSA. A screening visit and polysomnograms (PSGs) will be conducted to establish that each participant meets study enrollment criteria. The screening PSGs will serve as the baseline for the PSGs conducted during the 3rd and 4th weeks of drug treatment. Enrolled participants will be randomized to one of 5 parallel treatment arms. The first week of dosing will be with a lower dose run-in of AD109 (or corresponding single-drug component or placebo), followed by the full dose taken in weeks 2-4. One combination tablet is taken each night immediately before lights out. A total of approximately 260 participants will be enrolled. |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Samlet status | Not yet recruiting | ||||||||
| Startdato | 2021-09-30 | ||||||||
| Fullføringsdato | 2022-04-01 | ||||||||
| Primær sluttdato | 2022-04-01 | ||||||||
| Fase | Phase 2 | ||||||||
| Studietype | Interventional | ||||||||
| Primært utfall |
|
||||||||
| Sekundært utfall |
|
||||||||
| Registrering | 260 |
| Tilstand | |
|---|---|
| Innblanding |
Intervensjonstype: Drug Intervensjonsnavn: AD109 (atomoxetine/aroxybutynin) Beskrivelse: Matching (blinded) formulated AD109 oral tablet administered before sleep Intervensjonstype: Drug Intervensjonsnavn: Atomoxetine Hydrochloride Beskrivelse: Matching (blinded) formulated atomoxetine oral tablet administered before sleep Arm Group-etikett: Atomoxetine Intervensjonstype: Drug Intervensjonsnavn: Placebo Beskrivelse: Matching (blinded) formulated placebo oral tablet administered before sleep Arm Group-etikett: Placebo |
| Kvalifisering |
Kriterier:
Inclusion Criteria: - Between 18 to 65 years of age for men and 75 for women, inclusive - AHI between 10 to 45 with <25% events central or mixed apneas - BMI between 18.5 and 38 kg/m2 Exclusion Criteria: - Current clinically significant sleep disorder other than OSA - Clinically significant craniofacial malformation or grade ≥3 tonsillar hypertrophy. - Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 drugs for control (combination drugs count as 1 drug). - Clinically significant neurological disorder, including epilepsy/convulsions. - History of clinically significant urinary retention, gastric retention or other severe decreased gastrointestinal motility condition - Severe or frequent gastroesophageal reflux or constipation - Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first PSG and are not used during participation in the study Kjønn: All Minimumsalder: 18 Years Maksimal alder: 75 Years Sunne frivillige: No |
| Generell kontakt | Kontaktinformasjon vises kun når studiet rekrutterer emner. |
|---|
| Bekreftelsesdato |
2021-06-01 |
|---|---|
| Ansvarlig fest |
Type: Sponsor |
| Har utvidet tilgang | No |
| Tilstands Bla gjennom | |
| Antall våpen | 5 |
| Arm Group |
Merkelapp: AD109 Dose 1 Type: Experimental Beskrivelse: AD109 Dose 1 Merkelapp: AD109 Dose 2 Type: Experimental Beskrivelse: AD109 Dose 2 Merkelapp: AD109 Dose 3 Type: Experimental Beskrivelse: AD109 Dose 3 Merkelapp: Atomoxetine Type: Active Comparator Beskrivelse: Atomoxetine Merkelapp: Placebo Type: Placebo Comparator Beskrivelse: Placebo |
| Forkortelse | MARIPOSA |
| Pasientdata | No |
| Informasjon om studiedesign |
Tildeling: Randomized Intervensjonsmodell: Parallel Assignment Hovedformål: Treatment Maskering: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.